Cameron J. Wellard

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

Significant variations in first-line mantle cell lymphoma care-an Australasian Lymphoma and Related Diseases Registry study.

Significant variations in first-line mantle cell lymphoma care-an Australasian Lymphoma and Related Diseases Registry study.

Journal: Leukemia & lymphoma

Published: May 26, 2026

Underweight BMI Independently Predicts Inferior Survival in DLBCL Treated With R-CHOP: A Lymphoma Registry Study.

Underweight BMI Independently Predicts Inferior Survival in DLBCL Treated With R-CHOP: A Lymphoma Registry Study.

Journal: European journal of haematology

Published: April 14, 2026

Real-world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high-risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry.

Real-world application of the International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) consensus on genomic staging for high-risk multiple myeloma: A report from the Australia and New Zealand Myeloma and Related Diseases Registry.

Journal: British journal of haematology

Published: March 16, 2026

Prognostic survival models for diffuse large B-cell lymphoma using statistical and machine learning approaches.

Prognostic survival models for diffuse large B-cell lymphoma using statistical and machine learning approaches.

Journal: NPJ precision oncology

Published: March 02, 2026

Longitudinal Changes in Transfusion Practice in Myelodysplastic Syndromes: A Population Data-Linkage Study.

Longitudinal Changes in Transfusion Practice in Myelodysplastic Syndromes: A Population Data-Linkage Study.

Journal: European journal of haematology

Published: January 20, 2026

End-of-treatment positron emission tomography/computed tomography complete remission is highly prognostic in nodal peripheral T-cell lymphoma: An Australasian-Canadian collaborative study.

End-of-treatment positron emission tomography/computed tomography complete remission is highly prognostic in nodal peripheral T-cell lymphoma: An Australasian-Canadian collaborative study.

Journal: British journal of haematology

Published: December 29, 2025

Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk Groups.

Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk Groups.

Journal: Clinical lymphoma, myeloma & leukemia

Published: October 11, 2025

Development and Validation of Prognostic Models for Treatment Response of Patients with B-Cell Lymphoma: Standard Statistical and Machine-Learning Approaches.

Development and Validation of Prognostic Models for Treatment Response of Patients with B-Cell Lymphoma: Standard Statistical and Machine-Learning Approaches.

Journal: Journal of clinical medicine

Published: September 18, 2025

The Australian and New Zealand Massive Transfusion Registry: An innovation focusing on data collection, standardisation and interoperability between healthcare systems.

The Australian and New Zealand Massive Transfusion Registry: An innovation focusing on data collection, standardisation and interoperability between healthcare systems.

Journal: Health information management : journal of the Health Information Management Association of Australia

Published: September 18, 2025

No benefit from daratumumab, bortezomib and dexamethasone (D-Vd) in real-world patients with functional high-risk multiple myeloma: A report from the Myeloma and Related Diseases Registry.

No benefit from daratumumab, bortezomib and dexamethasone (D-Vd) in real-world patients with functional high-risk multiple myeloma: A report from the Myeloma and Related Diseases Registry.

Journal: British journal of haematology

Published: August 11, 2025

New Zealand Multiple Myeloma Patients Demonstrate Inferior Outcomes When Compared to Australian Counterparts - A Retrospective Cohort Study from the Myeloma and Related Diseases Registry (MRDR).

New Zealand Multiple Myeloma Patients Demonstrate Inferior Outcomes When Compared to Australian Counterparts - A Retrospective Cohort Study from the Myeloma and Related Diseases Registry (MRDR).

Journal: Clinical lymphoma, myeloma & leukemia

Published: August 01, 2025

Real-World Comparison of Treatment Outcomes for Multiple Myeloma in Elderly Transplant Ineligible Patients Receiving First-Line VRd, Rd and VCd: Results From the Australian and New Zealand Myeloma and Related Diseases Registry.

Real-World Comparison of Treatment Outcomes for Multiple Myeloma in Elderly Transplant Ineligible Patients Receiving First-Line VRd, Rd and VCd: Results From the Australian and New Zealand Myeloma and Related Diseases Registry.

Journal: Clinical lymphoma, myeloma & leukemia

Published: May 26, 2025

Showing 1-12 of 55

Last Updated: 09/26/2026